000963 华东医药
已收盘 08-18 15:00:00
资讯
新帖
简况
华东医药（000963）披露变更公司网址公告，8月17日股价下跌0.94%
证券之星 · 08-17 22:05
华东医药（000963）披露变更公司网址公告，8月17日股价下跌0.94%
华东医药：提议向全体股东每10股派3.50元人民币现金（含税）
证券之星 · 08-17 09:15
华东医药：提议向全体股东每10股派3.50元人民币现金（含税）
华东医药：创新转型国际化是公司既定核心长期战略
证券之星 · 08-11
华东医药：创新转型国际化是公司既定核心长期战略
华东医药：全资子公司医美产品获欧盟MDR CE认证
格隆汇 · 08-09
华东医药：全资子公司医美产品获欧盟MDR CE认证
华东医药最新公告：全资子公司医美产品获欧盟MDRCE认证
证券之星 · 08-09
华东医药最新公告：全资子公司医美产品获欧盟MDRCE认证
华东医药：MediBeacon® TGFR耗材已完成25个省份挂网
证券之星 · 08-07
华东医药：MediBeacon® TGFR耗材已完成25个省份挂网
华东医药：优先保障创新管线研发投入
证券之星 · 08-07
华东医药：优先保障创新管线研发投入
华东医药：HDM1005将面向超重或肥胖的广泛人群参与市场竞争
证券之星 · 08-07
华东医药：HDM1005将面向超重或肥胖的广泛人群参与市场竞争
华东医药集采答卷喜忧失衡 仿制药业务承压转型存多重考验
新浪证券 · 08-07
华东医药集采答卷喜忧失衡 仿制药业务承压转型存多重考验
华东医药：吡格列酮二甲双胍片未能中选是公司基于充分评估与审慎权衡后的理性抉择
证券之星 · 08-06
华东医药：吡格列酮二甲双胍片未能中选是公司基于充分评估与审慎权衡后的理性抉择
华东医药：已建立常态化管线评估与动态进退机制
证券之星 · 08-06
华东医药：已建立常态化管线评估与动态进退机制
华东医药：调配人员转向创新药等重点产品
证券之星 · 08-06
华东医药：调配人员转向创新药等重点产品
华东医药：炎朵®因合作方海外市场需求旺盛、产能分配受限，目前供货时间未定
证券之星 · 08-06
华东医药：炎朵®因合作方海外市场需求旺盛、产能分配受限，目前供货时间未定
华东医药：本次集采落地执行后仿制药核心品种阶段性经营压力有望充分释放
证券之星 · 08-06
华东医药：本次集采落地执行后仿制药核心品种阶段性经营压力有望充分释放
华东医药：海外具体启动时点将结合国内临床数据、海外市场及资源情况综合确定
证券之星 · 08-06
华东医药：海外具体启动时点将结合国内临床数据、海外市场及资源情况综合确定
华东医药：提议实施2026年中期利润分配方案
证券之星 · 08-06
华东医药：提议实施2026年中期利润分配方案
华东医药最新公告：环孢素等三款产品拟中选第十二批药品集采
证券之星 · 08-02
华东医药最新公告：环孢素等三款产品拟中选第十二批药品集采
华东医药(000963.SZ)董事长提议实施2026年中期利润分配方案 拟10派3.5元
智通财经 · 07-20
华东医药(000963.SZ)董事长提议实施2026年中期利润分配方案 拟10派3.5元
7月17日华东医药跌5.82%，创新药ETF银华基金重仓该股
证券之星 · 07-17
7月17日华东医药跌5.82%，创新药ETF银华基金重仓该股
华东医药：DR10624为长效三靶点激动剂
证券之星 · 07-17
华东医药：DR10624为长效三靶点激动剂
加载更多
公司概况
公司名称：
华东医药股份有限公司
所属行业：
零售业
上市日期：
2000-01-27
主营业务：
华东医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是商业、制造业、医美业务。
发行价格：
5.76
{"stockData":{"symbol":"000963","market":"SZ","secType":"STK","nameCN":"华东医药","latestPrice":28.94,"timestamp":1787036610000,"preClose":29.44,"halted":0,"volume":23299640,"delay":0,"changeRate":-0.017,"floatShares":1753000000,"shares":1754000000,"eps":1.9968,"marketStatus":"已收盘","change":-0.5,"latestTime":"08-18 15:00:00","open":29.47,"high":29.56,"low":28.89,"amount":678000000,"amplitude":0.0228,"askPrice":28.95,"askSize":113,"bidPrice":28.94,"bidSize":981,"shortable":0,"etf":0,"ttmEps":1.9968,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787103000000},"marketStatusCode":5,"adr":0,"adjPreClose":29.44,"symbolType":"stock","openAndCloseTimeList":[[1787016600000,1787023800000],[1787029200000,1787036400000]],"highLimit":32.38,"lowLimit":26.5,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1753736848,"isCdr":false,"pbRate":2.01,"roa":"--","peRate":14.493189,"roe":"3.97%","epsLYR":1.9484,"committee":0.574598,"marketValue":50753000000,"turnoverRate":0.0133,"status":1,"floatMarketCap":50732000000},"requestUrl":"/m/hq/s/000963/","defaultTab":"news","newsList":[{"id":"2660433105","title":"华东医药（000963）披露变更公司网址公告，8月17日股价下跌0.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660433105","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660433105?lang=zh_cn&edition=full","pubTime":"2026-08-17 22:05","pubTimestamp":1786975502,"startTime":"0","endTime":"0","summary":"截至2026年8月17日收盘，华东医药报收于29.44元，较前一交易日下跌0.94%，最新总市值为516.3亿元。该股当日开盘29.65元，最高29.71元，最低28.7元，成交额达8.61亿元，换手率为1.68%。近日，华东医药股份有限公司发布关于变更公司网址的公告。公告显示，公司根据业务发展需要，对公司网址进行变更，原网址www.eastchinapharm.com变更为www.huadongmedicine.com。新网址已正式启用，公司办公地址、投资者联系电话、传真、电子信箱等其他联系方式保持不变。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700034809.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0175","000963","BK0132","BK0183","BK0209","LU1969619763.USD","LU2328871848.SGD","BK0187","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660106685","title":"华东医药：提议向全体股东每10股派3.50元人民币现金（含税）","url":"https://stock-news.laohu8.com/highlight/detail?id=2660106685","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660106685?lang=zh_cn&edition=full","pubTime":"2026-08-17 09:15","pubTimestamp":1786929310,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药08月17日在投资者关系平台上答复投资者关心的问题。谢谢华东医药回复：您好！为切实回馈股东、传递管理层长期发展信心，公司近期发布《关于公司董事长提议实施2026年中期利润分配方案的公告》，在符合相关法律法规及《公司章程》规定的利润分配政策前提下，提议向全体股东每10股派3.50元人民币现金（含税），以公司目前总股本计算，预计2026年中期分红总额为613,807,896.80元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700002615.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0196","000963","CNHmain","BK0132","MUCmain","UCmain","LU1969619763.USD","BK0187","BK0175","BK0209","CYB","LU2328871848.SGD","MCNHmain","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658918734","title":"华东医药：创新转型国际化是公司既定核心长期战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2658918734","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658918734?lang=zh_cn&edition=full","pubTime":"2026-08-11 20:51","pubTimestamp":1786452690,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药08月10日在投资者关系平台上答复投资者关心的问题。创新转型国际化是公司既定核心长期战略，并非起步筹备阶段，早已多路径推进：创新药板块开展中美双报与海外临床，部分管线获 FDA 批件，同步探索对外授权；医美以 Sinclair 为全球化平台，推进海外注册，产品销售覆盖全球多国；工业微生物推进海外DMF注册，拓展全球客户。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081100035780.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","LU2328871848.SGD","BK0132","BK0188","BK0196","LU1969619763.USD","BK0187","000963","BK0175","BK0209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658351674","title":"华东医药：全资子公司医美产品获欧盟MDR CE认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2658351674","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658351674?lang=zh_cn&edition=full","pubTime":"2026-08-09 16:11","pubTimestamp":1786263086,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1969619763.USD","BK0187","BK0209","BK0188","BK0132","BK0183","000963","LU2328871848.SGD","BK0196","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658743936","title":"华东医药最新公告：全资子公司医美产品获欧盟MDRCE认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2658743936","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658743936?lang=zh_cn&edition=full","pubTime":"2026-08-09 16:10","pubTimestamp":1786263053,"startTime":"0","endTime":"0","summary":"华东医药(000963.SZ)公告称，公司英国全资子公司Sinclair旗下一款全新专利成分的注射用羧甲基壳聚糖溶液KIO015获得欧盟MDRCE认证，取得欧盟市场上市准入资格，系全球首款且目前唯一一款创新型非动物源性壳聚糖医美注射产品。该产品用于真皮内注射，表浅填充，肤质改善，皮肤补水。公司正推进该产品在中国市场的上市，预计2027年初递交上市申请。该事项不会对公司当前财务状况和经营成果产生重大影响。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。相关 ETF","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080900003997.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","000963","BK0187","BK0183","BK0196","BK0175","BK0188","LU1969619763.USD","LU2328871848.SGD","BK0209","FESXmain","FSXEmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657646532","title":"华东医药：MediBeacon® TGFR耗材已完成25个省份挂网","url":"https://stock-news.laohu8.com/highlight/detail?id=2657646532","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657646532?lang=zh_cn&edition=full","pubTime":"2026-08-07 20:51","pubTimestamp":1786107092,"startTime":"0","endTime":"0","summary":"MediBeacon TGFR目前国内商业化正有序推进，截至2026年一季报发布，MediBeacon TGFR耗材已完成25个省份挂网，瑞玛比嗪注射液已完成21个省份挂网。目前MediBeacon TGFR已被纳入《中国慢性肾脏病筛查、诊断及治疗临床实践指南》及《中国老年共病人群急性肾损伤的评估与诊断专家共识》；瑞玛比嗪注射液已申报2026年国家基本医疗保险、生育保险和工伤保险药品目录及商业健康保险创新药品目录，有望为后续市场拓展奠定良好基础。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700038559.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0187","BK0196","LU2328871848.SGD","BK0188","BK0132","BK0175","BK0209","LU1969619763.USD","000963"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657364651","title":"华东医药：优先保障创新管线研发投入","url":"https://stock-news.laohu8.com/highlight/detail?id=2657364651","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657364651?lang=zh_cn&edition=full","pubTime":"2026-08-07 20:51","pubTimestamp":1786107086,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药08月06日在投资者关系平台上答复投资者关心的问题。公司高度关注股价表现及公司内在价值匹配度，重视股东回报。公司现金流整体稳健，资金分配上优先保障创新管线研发投入，审慎开展契合战略的产业并购，同时兼顾股东回报，落实分红等相关安排。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700038554.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0196","000963","BK0132","LU1969619763.USD","LU2328871848.SGD","BK0183","BK0175","BK0209","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657565646","title":"华东医药：HDM1005将面向超重或肥胖的广泛人群参与市场竞争","url":"https://stock-news.laohu8.com/highlight/detail?id=2657565646","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657565646?lang=zh_cn&edition=full","pubTime":"2026-08-07 20:51","pubTimestamp":1786107075,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药08月06日在投资者关系平台上答复投资者关心的问题。投资者提问：HDM1005减重Ⅲ期40周顶线数据即将成为重要里程碑。HDM1005目前正在开展Ⅲ期临床试验。根据此前II期临床试验数据，HDM1005减重疗效显著，安全性、耐受性良好，同时还观察到在糖代谢、血压和血脂等其他心血管、代谢指标上的显著改善。商业化上，HDM1005将面向超重或肥胖的广泛人群参与市场竞争。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700038546.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0209","000963","LU2328871848.SGD","BK0188","BK0183","BK0196","BK0175","LU1969619763.USD","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657869828","title":"华东医药集采答卷喜忧失衡 仿制药业务承压转型存多重考验","url":"https://stock-news.laohu8.com/highlight/detail?id=2657869828","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657869828?lang=zh_cn&edition=full","pubTime":"2026-08-07 10:45","pubTimestamp":1786070700,"startTime":"0","endTime":"0","summary":"近日，华东医药披露第十二批国家药品集采拟中选结果，3款产品中标、4款核心品种落标，落选产品营收规模大幅超过中标品种，直接给公司仿制药板块带来收入下滑压力。按照集采规则，公立医疗机构将优先保障中选品种约定采购量，华东医药明确承认，落标品种会出现院内采购量流失、市场份额收缩，业绩下行压力客观存在。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-08-07/doc-inimnent3195583.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0183","LU2328871848.SGD","BK0132","BK0188","BK0196","LU1969619763.USD","BK0187","000963","BK0175","BK0209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657634330","title":"华东医药：吡格列酮二甲双胍片未能中选是公司基于充分评估与审慎权衡后的理性抉择","url":"https://stock-news.laohu8.com/highlight/detail?id=2657634330","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657634330?lang=zh_cn&edition=full","pubTime":"2026-08-06 20:51","pubTimestamp":1786020715,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药08月05日在投资者关系平台上答复投资者关心的问题。公司针对本次集采各产品的投标方案及各类可能结果已提前开展统筹规划、充分预判，本次拟中选结果整体符合公司预期。吡格列酮二甲双胍片未能中选，是公司基于充分评估与审慎权衡后的理性抉择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600037581.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0188","BK0132","LU2328871848.SGD","BK0196","BK0209","BK0187","LU1969619763.USD","000963","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657863306","title":"华东医药：已建立常态化管线评估与动态进退机制","url":"https://stock-news.laohu8.com/highlight/detail?id=2657863306","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657863306?lang=zh_cn&edition=full","pubTime":"2026-08-06 16:33","pubTimestamp":1786005195,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药08月06日在投资者关系平台上答复投资者关心的问题。公司内部已建立常态化管线评估与动态进退机制，定期从临床价值、竞争格局、商业化潜力、投入产出等多维度对全部在研项目进行综合复盘评估，持续优化管线结构，对评估后价值不及预期的项目，会审慎采取暂停、终止或其他处置方式，集中资源投向核心潜力项目。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600026958.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0183","LU1969619763.USD","BK0196","BK0187","BK0188","BK0209","LU2328871848.SGD","000963","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657686350","title":"华东医药：调配人员转向创新药等重点产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2657686350","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657686350?lang=zh_cn&edition=full","pubTime":"2026-08-06 16:33","pubTimestamp":1786005191,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药08月06日在投资者关系平台上答复投资者关心的问题。未来两年是否会出现销售人员及费用先投入、创新产品收入后兑现的阶段，从而影响医药工业利润率？面对集采带来的仿制药业务变化，公司正在对院内销售资源做结构性调整，调配具备专业能力的人员转向创新药等重点产品，搭建适配创新产品的学术推广体系。创新产品的市场导入期，客观上会需要进行一定投入。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600026956.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0209","LU1969619763.USD","LU2328871848.SGD","159992","000963","BK0175","06978","BK0196","BK1161","BK0187","BK0183","BK0188","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657686337","title":"华东医药：炎朵®因合作方海外市场需求旺盛、产能分配受限，目前供货时间未定","url":"https://stock-news.laohu8.com/highlight/detail?id=2657686337","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657686337?lang=zh_cn&edition=full","pubTime":"2026-08-06 16:30","pubTimestamp":1786005024,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药08月06日在投资者关系平台上答复投资者关心的问题。炎朵因合作方海外市场需求旺盛、产能分配受限，目前供货时间未定，公司正积极与合作方沟通，并同时做好相应预案，不排除使用法律手段维护公司合法权益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600026882.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0188","BK0209","000963","LU1969619763.USD","BK0196","LU2328871848.SGD","BK0183","BK0132","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657506861","title":"华东医药：本次集采落地执行后仿制药核心品种阶段性经营压力有望充分释放","url":"https://stock-news.laohu8.com/highlight/detail?id=2657506861","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657506861?lang=zh_cn&edition=full","pubTime":"2026-08-06 11:36","pubTimestamp":1785987398,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药08月05日在投资者关系平台上答复投资者关心的问题。本次集采落地执行后，公司仿制药核心品种由集中采购带来的阶段性经营压力有望得到充分释放，全面迈入创新药加速发展的崭新阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600015525.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0187","BK0196","LU2328871848.SGD","BK0188","BK0132","BK0175","BK0209","LU1969619763.USD","000963"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657506360","title":"华东医药：海外具体启动时点将结合国内临床数据、海外市场及资源情况综合确定","url":"https://stock-news.laohu8.com/highlight/detail?id=2657506360","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657506360?lang=zh_cn&edition=full","pubTime":"2026-08-06 11:36","pubTimestamp":1785987389,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药(000963)08月05日在投资者关系平台上答复投资者关心的问题。投资者提问：您好董秘，公司的1002和1005几个国内三期临床已经接近尾声，请问下海外临床到底还开启吗，还请明确回复，谢谢华东医药回复：您好！上述产品公司当前优先完成国内 III 期临床，海外具体启动时点将结合国内临床数据、海外市场及资源情况综合确定，如进入实质推进阶段，公司将及时披露。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。相关 ETF责任编辑：陈思雨","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600015507.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0209","BK0187","BK0188","LU2328871848.SGD","BK0183","BK0175","000963","BK0196","LU1969619763.USD","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657040505","title":"华东医药：提议实施2026年中期利润分配方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2657040505","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657040505?lang=zh_cn&edition=full","pubTime":"2026-08-06 11:33","pubTimestamp":1785987187,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药08月05日在投资者关系平台上答复投资者关心的问题。为切实回馈股东、传递管理层长期发展信心，公司近期发布《关于公司董事长提议实施2026年中期利润分配方案的公告》，在符合相关法律法规及《公司章程》规定的利润分配政策前提下，提议向全体股东每10股派3.50元人民币现金（含税），以公司目前总股本计算，预计2026年中期分红总额为613,807,896.80元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600015289.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0183","LU1969619763.USD","BK0196","BK0187","BK0188","BK0209","LU2328871848.SGD","000963","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656931272","title":"华东医药最新公告：环孢素等三款产品拟中选第十二批药品集采","url":"https://stock-news.laohu8.com/highlight/detail?id=2656931272","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656931272?lang=zh_cn&edition=full","pubTime":"2026-08-02 16:19","pubTimestamp":1785658785,"startTime":"0","endTime":"0","summary":"华东医药(000963.SZ)公告称，公司及全资子公司参与第十二批国家药品集中带量采购，环孢素软胶囊、他克莫司胶囊、美沙拉秦肠溶片拟中选。2025年度上述产品合计销售收入约20.76亿元，占营收4.76%。另有艾沙康唑注射剂等四款产品未中选，2025年度合计销售收入约46.34亿元，占营收10.62%，预计院内市场份额将下降。公司已制定经营预案应对集采压力。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。相关 ETF","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080200006696.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0188","000963","BK0196","LU2328871848.SGD","LU1969619763.USD","BK0132","BK0209","BK0187","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652261223","title":"华东医药(000963.SZ)董事长提议实施2026年中期利润分配方案 拟10派3.5元","url":"https://stock-news.laohu8.com/highlight/detail?id=2652261223","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652261223?lang=zh_cn&edition=full","pubTime":"2026-07-20 11:54","pubTimestamp":1784519697,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华东医药(000963.SZ)发布公告，公司董事长吕梁先生提议，在符合相关法律法规及《公司章程》规定的利润分配政策前提下，依据公司于2026年05月20日召开的2025年度股东会对董事会的授权，提议以公司未来实施2026年中期利润分配方案的股权登记日的总股本为基数，向全体股东每10股派3.50元现金(含税)，不送红股，不以资本公积转增股本。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469617.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000963","BK0175","LU2328871848.SGD","LU1969619763.USD","BK0132","BK0183","BK0187","BK0188","BK0196","BK0209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652405038","title":"7月17日华东医药跌5.82%，创新药ETF银华基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652405038","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652405038?lang=zh_cn&edition=full","pubTime":"2026-07-17 16:38","pubTimestamp":1784277532,"startTime":"0","endTime":"0","summary":"证券之星消息，7月17日华东医药跌5.82%，收盘报30.1元，换手率2.13%，成交量37.3万手，成交额11.41亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共45家，其中持有数量最多的公募基金为银华基金的创新药ETF银华。创新药ETF银华目前规模为151.77亿元，最新净值0.908，较上一交易日下跌0.27%，近一年上涨6.89%。创新药ETF银华的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700030258.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159316","BK0175","BK0188","BK0187","BK0183","LU1969619763.USD","BK0209","000963","BK0132","BK0196","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652457473","title":"华东医药：DR10624为长效三靶点激动剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2652457473","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652457473?lang=zh_cn&edition=full","pubTime":"2026-07-17 08:43","pubTimestamp":1784248986,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药07月16日在投资者关系平台上答复投资者关心的问题。近期关注到DR10624已布局高甘油三酯血症、MASLD、MASH、肥胖、2型糖尿病及HFpEF/HFmrEF等多个适应症。DR10624 为长效三靶点激动剂，具备代谢综合调节潜力。目前该产品正围绕高甘油三酯血症、MASLD、HFpEF/HFrEF等多适应症进行开发。公司将结合临床研究进展持续评估拓展新适应症，力争打造覆盖内分泌代谢及心血管疾病的差异化产品。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700007597.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1969619763.USD","BK0132","BK0175","000963","BK0209","BK0188","BK0183","LU2328871848.SGD","BK0196","BK0187"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787096820886,"stockEarnings":[{"period":"1week","weight":-0.0292},{"period":"1month","weight":-0.0385},{"period":"3month","weight":-0.0029},{"period":"6month","weight":-0.1791},{"period":"1year","weight":-0.3258},{"period":"ytd","weight":-0.2509}],"compareEarnings":[{"period":"1week","weight":0.0143},{"period":"1month","weight":0.0601},{"period":"3month","weight":-0.0413},{"period":"6month","weight":-0.0225},{"period":"1year","weight":0.0704},{"period":"ytd","weight":0.0054}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"华东医药股份有限公司","boardCode":"AI0052","boardName":"零售业","stockholders":"84304人(较上一季度增加26.48%)","perCapita":"20793股","listingDate":"2000-01-27","address":"浙江省杭州市拱墅区中山北路439号4、7楼","registeredCapital":"175373万元","survey":" 华东医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是商业、制造业、医美业务。","listedPrice":5.76},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华东医药(000963)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华东医药(000963)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华东医药,000963,华东医药股票,华东医药股票老虎,华东医药股票老虎国际,华东医药行情,华东医药股票行情,华东医药股价,华东医药股市,华东医药股票价格,华东医药股票交易,华东医药股票购买,华东医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华东医药(000963)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华东医药(000963)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}